Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab for anemia in low- or intermediate-1-risk myelodysplastic syndrome
2011-000261-12Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Siltuximab plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoint: Reduction in RBC transfusions. Started Jun 2011; status: completed.
02
Drugs
siltuximab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2011-000261-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000261-12.